SCHEDULE 13D
| | | | |
CUSIP NO. 68404L201 | | | | Page 7 of 11 Pages |
Explanatory Note
This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D (the “New Schedule 13D”) relating to the common stock, $0.01 par value per share (“Common Stock”), of Option Care Health, Inc., a Delaware corporation (the “Issuer”), originally filed with the Securities and Exchange Commission (the “SEC”) on December 17, 2021.
Terms used but not defined in this Amendment No. 8 have the respective meanings given to such terms in the original New Schedule 13D, as previously amended.
Item 4. Purpose of Transaction.
Item 4 is amended and supplemented as follows by adding the following:
August 2022 Equity Offering
On August 16, 2022, the Issuer and HC I entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC (the “Underwriter”). Pursuant to the Underwriting Agreement, HC I sold 11,000,000 shares of common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”) to the Underwriter at a price of $33.01 per share (the “August 2022 Offering”), representing approximately 6.0% of the outstanding Common Stock as of July 25, 2022 (as represented by the Issuer in its most recently filed 10-Q on July 27, 2022). The closing of the August 2022 Offering is expected to occur on August 18, 2022.
From time to time, WBA Parent undertakes a review of its strategic and capital allocation priorities. As part of this review, WBA Parent may effect one or more further sales of Common Stock. Any such sales, which may be undertaken at any time without further notice, may take a number of forms, including registered public offerings effected pursuant to HC I’s registration rights under the Registration Rights Agreement (as defined in Item 6) (which offerings may be underwritten and/or marketed), unregistered or registered block trades, unregistered market or private sales, pledges, hedges, forward sales and other derivative transactions.
Decisions to effect any such sales, as well as the size and timing thereof, are also subject to a number of factors outside of the control of WBA Parent, including current and anticipated future trading prices of the shares of Common Stock or other securities of the Issuer, the financial condition, results of operations and prospects of the Issuer and general economic, financial market and industry conditions, other investment and/or business opportunities available to the Reporting Persons, strategic considerations in respect of the Reporting Persons, general stock market and economic conditions, tax considerations and other factors. WBA Parent will periodically consider such sales opportunistically based on such factors and, as a result, the ultimate number of shares of Common Stock that may be sold by WBA, if any, is not ascertainable.
In connection with the August 2022 Offering, each of HC I, the executive officers of the Issuer and certain of the Issuer’s directors affiliated with HC I entered into a 45-day “lock-up” agreement with the Underwriter, dated August 16, 2022 (collectively, the “Lock-up Agreements”). Under the Lock-up Agreements, each party to the Lock-up Agreements agreed that, without the prior written consent of the Underwriter, and subject to certain exceptions, they would not, for a period of 45 days from the date of the prospectus for the August 2022 Offering, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge or disposition, (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities, or (3) cause to be filed or confidentially submitted any registration statement for the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock.
The foregoing summaries of the Underwriting Agreement and the Lock-up Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement and the Form of Lock-up Agreement, copies of which are attached hereto as Exhibits 4 and 5, respectively, and are incorporated herein by reference.